Kymera Therapeutics Inc.

05/06/2021 | Press release | Distributed by Public on 05/06/2021 05:11

Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021